KR20140026334A - 노텀 펙틴아세틸에스터라제에 대한 항체 - Google Patents

노텀 펙틴아세틸에스터라제에 대한 항체 Download PDF

Info

Publication number
KR20140026334A
KR20140026334A KR1020137013390A KR20137013390A KR20140026334A KR 20140026334 A KR20140026334 A KR 20140026334A KR 1020137013390 A KR1020137013390 A KR 1020137013390A KR 20137013390 A KR20137013390 A KR 20137013390A KR 20140026334 A KR20140026334 A KR 20140026334A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137013390A
Other languages
English (en)
Korean (ko)
Inventor
로버트 조셉 주니어 브로마지
샤오 펑
석주 홍
그레고리 랜즈
제프 류
데이비드 조지 포터
데이비드 리드 파월
Original Assignee
렉시컨 파마슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 렉시컨 파마슈티컬스 인코퍼레이티드 filed Critical 렉시컨 파마슈티컬스 인코퍼레이티드
Publication of KR20140026334A publication Critical patent/KR20140026334A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020137013390A 2010-11-24 2011-11-22 노텀 펙틴아세틸에스터라제에 대한 항체 Ceased KR20140026334A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41692710P 2010-11-24 2010-11-24
US61/416,927 2010-11-24
PCT/US2011/061785 WO2012071381A1 (en) 2010-11-24 2011-11-22 Antibodies to notum pectinacetylesterase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016214A Division KR20180069083A (ko) 2010-11-24 2011-11-22 노텀 펙틴아세틸에스터라제에 대한 항체

Publications (1)

Publication Number Publication Date
KR20140026334A true KR20140026334A (ko) 2014-03-05

Family

ID=46146184

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137013390A Ceased KR20140026334A (ko) 2010-11-24 2011-11-22 노텀 펙틴아세틸에스터라제에 대한 항체
KR1020187016214A Ceased KR20180069083A (ko) 2010-11-24 2011-11-22 노텀 펙틴아세틸에스터라제에 대한 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187016214A Ceased KR20180069083A (ko) 2010-11-24 2011-11-22 노텀 펙틴아세틸에스터라제에 대한 항체

Country Status (21)

Country Link
US (3) US20130302346A1 (enExample)
EP (1) EP2643019B1 (enExample)
JP (1) JP6033229B2 (enExample)
KR (2) KR20140026334A (enExample)
CN (1) CN103298490B (enExample)
AU (1) AU2011332007C1 (enExample)
BR (1) BR112013012858B1 (enExample)
CA (1) CA2817415C (enExample)
CO (1) CO6721048A2 (enExample)
DK (1) DK2643019T3 (enExample)
ES (1) ES2718849T3 (enExample)
HU (1) HUE043576T2 (enExample)
IL (1) IL225876A0 (enExample)
MX (2) MX357166B (enExample)
NZ (1) NZ609501A (enExample)
PL (1) PL2643019T3 (enExample)
PT (1) PT2643019T (enExample)
RU (1) RU2013123793A (enExample)
SG (1) SG189982A1 (enExample)
WO (1) WO2012071381A1 (enExample)
ZA (1) ZA201302983B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013113638A (ru) * 2010-08-27 2014-10-10 Стем Сентркс, Инк. МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HUE043576T2 (hu) 2010-11-24 2019-08-28 Lexicon Pharmaceuticals Inc Antitestek notum pektinacetilészterázhoz
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US8802365B2 (en) * 2011-03-22 2014-08-12 Whitehead Institute For Biomedical Research Methods for identifying candidate modulators of NOTUM activity
WO2014033252A1 (en) * 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
EP4129320A1 (en) 2015-02-19 2023-02-08 Compugen Ltd. Anti-pvrig antibodies and methods of use
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN110317271B (zh) * 2019-07-02 2021-04-30 武汉云克隆科技股份有限公司 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体
CA3202384A1 (en) * 2020-12-16 2022-06-23 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
GB0201808D0 (en) * 2002-01-25 2002-03-13 European Molecular Biology Lab Embl Protein
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
JP4643450B2 (ja) * 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
RU2013113638A (ru) * 2010-08-27 2014-10-10 Стем Сентркс, Инк. МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HUE043576T2 (hu) 2010-11-24 2019-08-28 Lexicon Pharmaceuticals Inc Antitestek notum pektinacetilészterázhoz

Also Published As

Publication number Publication date
AU2011332007A1 (en) 2013-05-09
AU2011332007C1 (en) 2017-03-02
MX2013005906A (es) 2013-06-28
US20160152731A1 (en) 2016-06-02
CO6721048A2 (es) 2013-07-31
EP2643019A4 (en) 2014-12-31
US11059907B2 (en) 2021-07-13
BR112013012858B1 (pt) 2021-12-07
ZA201302983B (en) 2017-06-28
CA2817415A1 (en) 2012-05-31
NZ609501A (en) 2014-12-24
AU2011332007B2 (en) 2016-11-10
SG189982A1 (en) 2013-06-28
EP2643019A1 (en) 2013-10-02
MX385858B (es) 2025-03-18
US20130302346A1 (en) 2013-11-14
CN103298490A (zh) 2013-09-11
DK2643019T3 (en) 2019-04-15
IL225876A0 (en) 2013-06-27
JP2014501513A (ja) 2014-01-23
US20190241677A1 (en) 2019-08-08
WO2012071381A1 (en) 2012-05-31
EP2643019B1 (en) 2019-01-02
CN103298490B (zh) 2017-04-26
HUE043576T2 (hu) 2019-08-28
CA2817415C (en) 2020-05-12
BR112013012858A2 (pt) 2018-09-04
ES2718849T3 (es) 2019-07-04
MX357166B (es) 2018-06-28
JP6033229B2 (ja) 2016-11-30
PT2643019T (pt) 2019-04-23
PL2643019T3 (pl) 2019-07-31
RU2013123793A (ru) 2014-12-27
KR20180069083A (ko) 2018-06-22

Similar Documents

Publication Publication Date Title
US11059907B2 (en) Antibodies that bind Notum Pectinacetylesterase
KR101307868B1 (ko) M-csf-특이적 단일클론 항체 및 그것의 사용
AU2016329120B2 (en) Bispecific antibodies specific for a costimulatory TNF receptor
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
CN110382542B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20170085552A (ko) Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자
CN114751989A (zh) 包含三聚体tnf家族配体的抗原结合分子
KR20140019385A (ko) 이중특이성 및 단일특이성, 비대칭성 항체 및 이의 제조방법
RU2853336C1 (ru) АНТИТЕЛО К OX40L, БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО К OX40L/TNFα И ИХ ПРИМЕНЕНИЕ
HK40069172B (zh) 包含三聚体tnf家族配体的抗原结合分子
KR20220081857A (ko) 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
HK40015870B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40015870A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer
HK1189166B (en) Antibodies to notum pectinacetylesterase
HK1189166A (en) Antibodies to notum pectinacetylesterase
HK1261508A1 (en) Bispecific antibodies specific for a costimulatory tnf receptor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130524

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171219

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180504

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180607

PJ0201 Trial against decision of rejection

Patent event date: 20180607

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180504

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190920

Appeal identifier: 2018101002417

Request date: 20180607

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002417; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180607

Effective date: 20190920

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190920

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180607

Decision date: 20190920

Appeal identifier: 2018101002417